The ability of cancer cells to metastasize, or spread from one part of the body to another, is one of the reasons why cancer can be extremely challenging to treat.
Immuno-oncology startup launches with $150 million, ex-Surface, Bluebird exec as CEO
Robert Ross had thought he would take more time off after his previous company, Surface Oncology, was acquired in September. The immuno-oncology firm had just